Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy
Executive Summary
Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA
You may also be interested in...
Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women
Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.
Wyeth Using Unbranded Ads To Stimulate Premarin, Prempro Growth
Wyeth's latest direct-to-consumer advertising campaign for its estrogen franchise suggests emerging use of unbranded ads for leading products in mature markets
Wyeth Using Unbranded Ads To Stimulate Premarin, Prempro Growth
Wyeth's latest direct-to-consumer advertising campaign for its estrogen franchise suggests emerging use of unbranded ads for leading products in mature markets